生物类改善病情抗风湿药治疗期间严重感染包括结核分枝杆菌感染的评估:治疗线数是否重要
基于英国风湿病学会生物制剂注册队列中33 897个治疗疗程(62 513患者年)的类风湿关节炎患者,评估七种生物类改善病情抗风湿药在不同治疗线数下严重感染和活动性结核的发生率。调整混杂后阿达木单抗和英夫利西单抗的严重感染风险略高于依那西普,但按治疗线数分层未见明确规律;49例结核均发生在前三线治疗且2009年后罕见。结论认为严重感染风险似乎不受治疗线数影响,而结核风险似乎在初始治疗线数或2009年前更常见。
要点
- 33 897个治疗疗程中严重感染发生率为4.4/100患者年(95%CI 4.2, 4.5)。
- 调整后阿达木单抗和英夫利西单抗的严重感染风险略高于依那西普。
- 按治疗线数分层后严重感染发生率或风险比未见明确规律。
核心结论
- 类风湿关节炎患者中严重感染风险似乎不受治疗线数影响,而结核风险似乎在初始治疗线数或2009年前更常见。
研究设计与样本
- 基于英国风湿病学会类风湿关节炎生物制剂注册队列,纳入从第一至第五线治疗开始使用依那西普、培塞利珠单抗、英夫利西单抗、阿达木单抗、阿贝西单抗、利妥昔单抗或托珠单抗的类风湿关节炎患者,随访最长3年。
主要发现
- 33 897个治疗疗程(62 513患者年)中严重感染发生率为4.4/100患者年(95%CI 4.2, 4.5)。
- 调整后阿达木单抗和英夫利西单抗的严重感染风险比略高于依那西普。
- 按治疗线数分层后严重感染的发生率或风险比未见明确规律。
- 敏感性分析显示这些治疗的风险比相似。
- 49例结核均发生在治疗的前三线且2009年后罕见。
关键数值与推荐
- 主要结局为严重感染,次要结局为结核。
- 采用Cox比例风险模型并以逆概率治疗加权控制混杂。
- 敏感性分析限制在2009年(托珠单抗可及)至研究结束(2018年)的所有治疗疗程。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to evaluate if and how the incidence of serious infection (SI) and active tuberculosis (TB) differ among seven biologic DMARDs (bDMARDs) in patients with RA considering the line of therapy. METHODS: Patients with RA from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) cohort who initiated etanercept, certolizumab, infliximab, adalimumab, abatacept, rituximab or tocilizumab from the first to fifth line of therapy were included. Follow-up extended up to 3 years. The primary outcome was SI and the secondary outcome was TB. Event rates were calculated and compared using Cox proportional hazards models, controlling for confounding with inverse probability of treatment weights. Comparisons were made overall and stratified by line of therapy. Sensitivity analysis was restricted to all treatment courses from 2009 (tocilizumab availability) until the end of the study (2018). RESULTS: Among 33 897 treatment courses (62 513 patient-years) the incidence of SI was 4.4/100 patient-years (95% CI 4.2, 4.5). After adjustment, hazards ratios (HRs) of SI were slightly higher with adalimumab and infliximab compared with etanercept. However, no clear pattern was observed when stratifying by line of therapy in terms of incidence rate or HR. Sensitivity analyses showed similar HRs among these treatments. Regarding TB, all 49 cases occurred during the first three lines of treatment and rarely since 2009. CONCLUSION: The risk of serious infections does not appear to be influenced by the line of therapy in patients with RA. However, the risk of TB seems to be more frequent during the initial lines of treatment or prior to 2009.
引用
- Lauper K, Kearsley-Fleet L, Galloway JB, et al. Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter? Rheumatology (Oxford). 2024. PMID: 37758229. doi:10.1093/rheumatology/kead515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。